Abstract:Abstract Background Intensive evidence has highlighted the effect of aberrant alternative splicing (AS) events on cancer progression when triggered by dysregulation of the SR protein family. Nonetheless, the underlying mechanism in breast cancer (BRCA) remains elusive. Here we sought to explore the molecular function of SRSF1 and identify the key AS events regulated by SRSF1 in BRCA. Methods We conducted a comprehensive analysis of the expression and clinical correlation of SRSF1 in BRCA based on the TCGA dataset, Metabric database and clinical tissue samples. Functional analysis of SRSF1 in BRCA was conducted in vitro and in vivo. SRSF1-mediated AS events and their binding motifs were identified by RNA-seq, RNA immunoprecipitation-PCR (RIP-PCR) and in vivo crosslinking followed by immunoprecipitation (CLIP), which was further validated by the minigene reporter assay. PTPMT1 exon 3 (E3) AS was identified to partially mediate the oncogenic role of SRSF1 by the P-AKT/C-MYC axis. Finally, the expression and clinical significance of these AS events were validated in clinical samples and using the TCGA database. Results SRSF1 expression was consistently upregulated in BRCA samples, positively associated with tumor grade and the Ki-67 index, and correlated with poor prognosis in a hormone receptor-positive (HR+) cohort, which facilitated proliferation, cell migration and inhibited apoptosis in vitro and in vivo. We identified SRSF1-mediated AS events and discovered the SRSF1 binding motif in the regulation of splice switching of PTPMT1. Furthermore, PTPMT1 splice switching was regulated by SRSF1 by binding directly to its motif in E3 which partially mediated the oncogenic role of SRSF1 by the AKT/C-MYC axis. Additionally, PTPMT1 splice switching was validated in tissue samples of BRCA patients and using the TCGA database. The high-risk group, identified by AS of PTPMT1 and expression of SRSF1, possessed poorer prognosis in the stage I/II TCGA BRCA cohort. Conclusions SRSF1 exerts oncogenic roles in BRCA partially by regulating the AS of PTPMT1, which could be a therapeutic target candidate in BRCA and a prognostic factor in HR+ BRCA patient.

PTBP1 and PTBP2 Impaired Autoregulation of SRSF3 in Cancer Cells

Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression.

Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1

Oncogenic SRSF3 in Health and Diseases.

A Genome Landscape of SRSF3-regulated Splicing Events and Gene Expression in Human Osteosarcoma U2OS Cells.

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer

SRSF3 Suppresses RCC Tumorigenesis and Progression Via Regulating SP4 Alternative Splicing

Factors affecting the expression and stability of full-length and truncated SRSF3 proteins in human cancer cells

SRSF1 Modulates PTPMT1 Alternative Splicing to Regulate Lung Cancer Cell Radioresistance

SRSF1 Prevents DNA Damage and Promotes Tumorigenesis Through Regulation of DBF4B Pre-mRNA Splicing.

SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes

The Alternative Splicing of Intersectin 1 Regulated by PTBP1 Promotes Human Glioma Progression.

Targeting Splicing Factor SRSF6 for Cancer Therapy

PCBP1 Inhibits the Expression of Oncogenic STAT3 Isoform by Targeting Alternative Splicing of STAT3 Exon 23

Biological Function and Molecular Mechanism of SRSF3 in Cancer and Beyond (Review)

SRSF3 Functions As an Oncogene in Colorectal Cancer by Regulating the Expression of ArhGAP30

SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells

PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2

RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing

Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor: GUO and JIA